A key US Republican senator said he’s launched an investigation into the Food and Drug Administration’s recent denials of ...

Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.

VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect ...

The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now denying the biotech’s claims about a sham trial request for the rare ...

Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.

As of Friday, March 06, Solid Biosciences Inc.’s SLDB share price has surged by 13.19%, which has investors questioning if this is right time to sell.

Emily Felix, a trainee solicitor from Gowran, was first diagnosed with the largely unheard-of Friedreich’s Ataxia in September 2010 at just 12 years of age, a diagnosis that would change her life ...

Shares in PepGen were down more than 21% after the FDA placed a partial clinical hold on its lead drug PGN-EDODM1, for rare ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its ...

Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need to be even stricter with its expenditures. | Biohaven is powering ahead ...

Drivers must understand the nature of not disclosing medical conditions to the DVLA ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities ...